July 13, 2022 News by Steve Bryson, PhD For MS Patients in Japan, Kesimpta May Be Best at Preventing Relapses Kesimpta (ofatumumab) may be more effective at reducing relapse rates than other disease-modifying therapies (DMTs) in Japanese adults with relapsing forms of multiple sclerosis (MS), according to a review of clinical trial data. Although the differences were not statistically significant, the study provided comparative evidence that may help…
January 18, 2022 News by Margarida Maia, PhD Gilenya Shows Long-term Efficacy, Safety in Real-world RRMS Study Long-term treatment with Gilenya (fingolimod) in routine clinical practice is safe and effective for relapsing-remitting multiple sclerosis (RRMS), a five-year study in Germany of more than 4,000 patients reported. Over time, relapses in the majority of study patients who continued with Gilenya became less common and less severe,…
December 29, 2021 News by Steve Bryson, PhD Higher, Fewer Copaxone Doses Lowered Relapse Rates Over 7 YearsĀ A higher dose of Copaxone (glatiramer acetate) given three times weekly over seven years led to sustainably lower relapse rates and slowed disability progression inĀ multiple sclerosis (MS) patients, according to a long-term analysis of the GALA study. The higher dose āĀ 40 mg/mL ā was generally well-tolerated with no…
October 18, 2021 News by Marta Figueiredo, PhD #ECTRIMS2021 ā Early Ocrevus Slows MS Better Versus 2-year Delay Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ here to see the latest stories from the conference. Early use of…
May 5, 2021 News by Steve Bryson, PhD Relapsing MS Patients May Fare Better on Zeposia Than Aubagio Treatment with Zeposia (ozanimod) significantly reduces the risk of relapse, decreases the proportion of patients experiencing a relapse, and has a better safety profile than Aubagio (teriflunomide) for people with relapsing multiple sclerosis (MS), according to an indirect comparison of clinical trial data.
December 14, 2020 News by Marta Figueiredo, PhD Ublituximab Superior to Aubagio at Lowering Relapse Rates, Phase 3 Data Show Ublituximab, an investigational anti-CD20 antibody, outperformed Aubagio (teriflunomide) in lowering the frequency of relapses among people with active, relapsing forms of multiple sclerosis (MS), according to top-line data from the Phase 3 ULTIMATE trials. Full results, including data on safety and secondary goals, are expected to be presented…
July 6, 2020 News by Marta Figueiredo, PhD Tecfidera Safe and Effective in Hispanic/Latino MS Patients, Real-world Data Show TecfideraĀ (dimethyl fumarate) is as safe and effective in Hispanic/LatinoĀ multiple sclerosisĀ (MS) patients as it is in their non-Hispanic and non-Latino peers, three-year data from a real-world study show. These interim findings, based on the largest group of Tecfidera-treated Hispanic and Latino MS patients studied to date, support the therapyās…
September 3, 2019 News by Jose Marques Lopes, PhD Ofatumumab Better at Easing Relapse Rates and Slowing MS Progression Than Aubagio, Phase 3 Data Show Monthly injections of ofatumumabĀ led to more clinically meaningful reductions in relapse rates and delayed disability progression than did daily treatment withĀ AubagioĀ (teriflunomide) tablets in people with relapsing forms of multiple sclerosisĀ (MS), results from two Phase 3 trials showed. Ofatumumab, formerly known as OMB157, is a potent, self-administered…
April 25, 2019 News by Vijaya Iyer, PhD Aubagio Lowers Relapse Rate in RRMS Patients, Real-world Observational Study Shows In clinical practice, relapse events dropped by roughly half over a four-year period inĀ relapsing-remitting multiple sclerosisĀ (RRMS) patients treated withĀ Aubagio (teriflunomide), a real-world study reports. The study, āReal-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study,ā also examined patients’ perspectives in…
February 20, 2017 News by Patricia Silva, PhD Ozanimod Reduces Multiple Sclerosis Relapse Rate, Phase 3 Trial Shows A Phase 3 clinical trial evaluating the safety and effectiveness of ozanimod (RPC-1063) in patients withĀ relapsing multiple sclerosis (RMS)Ā shows treatment reduced the disease’s annualized relapse rate (ARR), researchers reported. The Phase 3 SUNBEAM trial (NCT02294058)Ā testedĀ ozanimod, anĀ oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator designed to…